Healthcare Technology
What Are Digital Biomarkers? How Wearable Technology Is Entering Drug Development
Clinical trials have traditionally measured patient outcomes through periodic clinic visits — a blood pressure reading, a questionnaire, a physical exam, captured at scheduled intervals weeks or months apart. Digital biomarkers offer a fundamentally different approach: continuous, objective measurement of a patient’s health status using wearable devices and sensors, generating far richer data than intermittent…
PharmaTher Establishes PERSONALIZ3D Personalized Medicine Platform
PharmaTher Holdings Ltd. (CSE: PHRM; OTCQB: PHRRF) is a Toronto-based life sciences company focused on personalized medicines and pharmaceutical 3D-printing technologies. The Canadian Securities Exchange lists 91,019,065 shares issued and outstanding. In its latest publicly available interim financial statements, the company reported C$794,804 in cash and no revenue to date as of February 28, 2026.…
Karyopharm Plans August FDA Filing for Selinexor Combination
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration in August 2026 for selinexor in combination with ruxolitinib as a treatment for myelofibrosis. The company said it will seek accelerated approval following discussions with the FDA.…
HLS Secures Broad Private Coverage for NILEMDO Across Canada
HLS Therapeutics Inc. (TSX: HLS), a specialty pharmaceutical company focused on cardiovascular and psychiatric treatments, has expanded Canadian reimbursement access for NILEMDO, its oral cholesterol-lowering medication. The company said it has secured reimbursement agreements with Canada’s largest private payers, which it estimates represent approximately 80% of privately insured Canadians. Most patients covered by those plans…
What Is a Liquid Biopsy? The Blood Test Changing Cancer Detection and Treatment
Traditional cancer diagnosis and monitoring has long relied on tissue biopsy — a surgical or needle procedure to physically remove a piece of tumor tissue for laboratory analysis. Liquid biopsy technology offers an alternative: detecting and characterizing cancer through a simple blood draw, by analyzing fragments of tumor DNA that circulate in the bloodstream. For…
What Is Gene Therapy? How It Differs from Gene Editing and Why the Distinction Matters
Gene therapy and gene editing are two of the most transformative — and most frequently confused — technologies in modern biotechnology. Both operate at the level of DNA and both aim to treat disease by addressing its genetic roots. But they work in fundamentally different ways, and that difference has important implications for which diseases…
What Is an Antibody-Drug Conjugate (ADC)? The Precision Oncology Technology Reshaping Cancer Treatment
Antibody-drug conjugates — universally known in biotech as ADCs — have become one of the most commercially successful and scientifically active areas of oncology drug development. With multiple blockbuster ADCs on the market and billions in pharmaceutical deal-making driven by ADC pipeline acquisitions, understanding what ADC technology is, how it works, and why the pharmaceutical…
What Is mRNA Technology? Beyond COVID Vaccines and Into the Future of Medicine
The COVID-19 pandemic brought mRNA technology from the laboratory into global consciousness, delivering two of the most rapidly developed and widely administered vaccines in history. But for biotech investors, the real significance of the mRNA platform is not what it accomplished in 2020 and 2021 — it is what it enables going forward. Moderna, BioNTech,…
What Is CAR-T Cell Therapy? Engineered Immune Cells and Their Biotech Investment Implications
CAR-T cell therapy represents one of the most significant advances in cancer treatment in decades — and one of the most technically complex, logistically challenging, and expensive therapeutic approaches ever brought to market. For biotech investors, CAR-T is both an established commercial reality and an active area of development where the next generation of therapies…
What Is AI in Drug Discovery? How Machine Learning Is Reshaping Biotech
Artificial intelligence has become one of the most discussed and most misunderstood concepts in the biotech sector. Some companies claim AI will compress the 15-year drug discovery timeline to a few years. Skeptics argue that AI-designed drugs are only as good as the biology they are trained on, and that the hard part of drug…
